INBX Latest Headlines

LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)

at www.tipranks.com (Sat, 16-May 10:35 AM)

Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

at www.tipranks.com (Fri, 15-May 8:45 AM)

Inhibrx Biosciences GAAP EPS of -$2.15

at seekingalpha.com (Thu, 14-May 4:46 PM)

INBRX-106 Combination Doubles Response Rate in Early HNSCC Study, Showing Clear Clinical Benefit Over Standard PD-1 Monotherapy

Market Chameleon (Mon, 11-May 8:16 AM)

Inhibrx Biosciences Reports Positive Interim Phase 2 Results

at www.tipranks.com (Mon, 11-May 5:13 PM)

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

at www.benzinga.com (Mon, 11-May 1:57 PM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)

at www.tipranks.com (Mon, 11-May 10:10 AM)

INBX Highlights: Ozekibart Shows Robust Disease Control Rate of 87% in Late-Line Colorectal Cancer—Durable Responses Outpace Historical Norms

Market Chameleon (Wed, 22-Apr 10:28 AM)

INBX’s Ozekibart Delivers 20% Response Rate and 87% Disease Control in Late-Line Colorectal Cancer—Durable Results in Tough-to-Treat Patients

Market Chameleon (Wed, 22-Apr 7:34 AM)

Inhibrx Cuts R&D Costs Sharply as Two Clinical Trials Push Toward Key 2026 Milestones

Market Chameleon (Fri, 20-Mar 10:59 AM)